We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bioverativ Inc. (delisted) | NASDAQ:BIVV | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 104.98 | 101.00 | 104.98 | 0 | 01:00:00 |
From Apr 2019 to Apr 2024
By Dana Mattioli and Jonathan D. Rockoff
Sanofi SA is nearing a deal to buy hemophilia drugmaker Bioverativ Inc. for more than $11.5 billion as the French drugmaker looks set to clinch a big deal while it braces for generic competition for its top-selling product.
A deal, which could be announced as soon as Monday, would value the former Biogen Inc. unit at $105 a share, according to people familiar with the matter. The price would represent a 63% premium to where Bioverativ closed trading Friday. It is possible the talks could fall apart before a deal is reached.
(More to come)
(END) Dow Jones Newswires
January 21, 2018 20:34 ET (01:34 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Bioverativ Inc. Chart |
1 Month Bioverativ Inc. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
